Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans

William G. Schrage, John H. Eisenach, Michael Joseph Joyner

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

In older humans, infusions of endothelial agonists suggest endothelial dysfunction, due in part to less nitric oxide (NO)- and prostaglandin (PG)-mediated vasodilatation, and a shift toward PG-mediated vasoconstriction. Ageing can also be associated with lower exercise blood flow (exercise hyperaemia), but the vascular mechanisms mediating this remain unknown. Notably, in young adults, inhibition of NO and PGs during exercise decreases exercise hyperaemia by ∼20 and ∼12% respectively. We tested our first hypothesis that in older humans inhibition of NO would decrease hyperaemia, but that inhibition of PGs would increase hyperaemia by blocking vasoconstrictor PGs. Fifteen older subjects (65 ± 3 years) performed dynamic forearm exercise for 20 min (20 contractions min-1). Forearm blood flow (FBF) was measured beat-to-beat with Doppler ultrasound, while saline or drugs were infused sequentially via brachial artery catheter in the exercising forearm. After achieving steady-state exercise, l-NAME (25 mg) was infused over 5 min to inhibit NO synthase. After a further 2 min of exercise (saline), ketorolac (6 mg) was infused over 5 min to inhibit PGs, followed by a futher 3 min of exercise with saline. Drug order was reversed in seven subjects. l-NAME reduced steady-state exercise hyperaemia by 12 ± 3% in older subjects (P < 0.01), whereas ketorolac had no net effect on blood flow (3 ± 6%, P > 0.4). The effects of l-NAME and ketorolac were independent of drug order. By comparing these results with our previous results in young adults, we tested our second hypothesis that in older humans inhibition of NO or PGs would have less impact on exercise hyperaemia due to less vasodilatation from these signals. Our results suggest that, compared with young adults, in older humans the relative contribution of NO to exercise hyperaemia is reduced ∼45% (22 ± 4 versus 12 ± 3%), but the role of PG in mediating vasodilatation is lost in ageing human skeletal muscle. Lower exercise hyperaemia in older humans may be mediated in part by less NO- and PG-mediated vasodilatation during exercise.

Original languageEnglish (US)
Pages (from-to)227-236
Number of pages10
JournalJournal of Physiology
Volume579
Issue number1
DOIs
StatePublished - Feb 15 2007
Externally publishedYes

Fingerprint

Vasodilation
Prostaglandins
Nitric Oxide
Exercise
Hyperemia
Forearm
Ketorolac
Young Adult
Pharmaceutical Preparations
Doppler Ultrasonography
Brachial Artery
Vasoconstrictor Agents
Vasoconstriction
Nitric Oxide Synthase
Blood Vessels
Skeletal Muscle
Catheters

ASJC Scopus subject areas

  • Physiology

Cite this

Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans. / Schrage, William G.; Eisenach, John H.; Joyner, Michael Joseph.

In: Journal of Physiology, Vol. 579, No. 1, 15.02.2007, p. 227-236.

Research output: Contribution to journalArticle

@article{36d05a20ea144a9c84e150f10182bf0f,
title = "Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans",
abstract = "In older humans, infusions of endothelial agonists suggest endothelial dysfunction, due in part to less nitric oxide (NO)- and prostaglandin (PG)-mediated vasodilatation, and a shift toward PG-mediated vasoconstriction. Ageing can also be associated with lower exercise blood flow (exercise hyperaemia), but the vascular mechanisms mediating this remain unknown. Notably, in young adults, inhibition of NO and PGs during exercise decreases exercise hyperaemia by ∼20 and ∼12{\%} respectively. We tested our first hypothesis that in older humans inhibition of NO would decrease hyperaemia, but that inhibition of PGs would increase hyperaemia by blocking vasoconstrictor PGs. Fifteen older subjects (65 ± 3 years) performed dynamic forearm exercise for 20 min (20 contractions min-1). Forearm blood flow (FBF) was measured beat-to-beat with Doppler ultrasound, while saline or drugs were infused sequentially via brachial artery catheter in the exercising forearm. After achieving steady-state exercise, l-NAME (25 mg) was infused over 5 min to inhibit NO synthase. After a further 2 min of exercise (saline), ketorolac (6 mg) was infused over 5 min to inhibit PGs, followed by a futher 3 min of exercise with saline. Drug order was reversed in seven subjects. l-NAME reduced steady-state exercise hyperaemia by 12 ± 3{\%} in older subjects (P < 0.01), whereas ketorolac had no net effect on blood flow (3 ± 6{\%}, P > 0.4). The effects of l-NAME and ketorolac were independent of drug order. By comparing these results with our previous results in young adults, we tested our second hypothesis that in older humans inhibition of NO or PGs would have less impact on exercise hyperaemia due to less vasodilatation from these signals. Our results suggest that, compared with young adults, in older humans the relative contribution of NO to exercise hyperaemia is reduced ∼45{\%} (22 ± 4 versus 12 ± 3{\%}), but the role of PG in mediating vasodilatation is lost in ageing human skeletal muscle. Lower exercise hyperaemia in older humans may be mediated in part by less NO- and PG-mediated vasodilatation during exercise.",
author = "Schrage, {William G.} and Eisenach, {John H.} and Joyner, {Michael Joseph}",
year = "2007",
month = "2",
day = "15",
doi = "10.1113/jphysiol.2006.124313",
language = "English (US)",
volume = "579",
pages = "227--236",
journal = "Journal of Physiology",
issn = "0022-3751",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans

AU - Schrage, William G.

AU - Eisenach, John H.

AU - Joyner, Michael Joseph

PY - 2007/2/15

Y1 - 2007/2/15

N2 - In older humans, infusions of endothelial agonists suggest endothelial dysfunction, due in part to less nitric oxide (NO)- and prostaglandin (PG)-mediated vasodilatation, and a shift toward PG-mediated vasoconstriction. Ageing can also be associated with lower exercise blood flow (exercise hyperaemia), but the vascular mechanisms mediating this remain unknown. Notably, in young adults, inhibition of NO and PGs during exercise decreases exercise hyperaemia by ∼20 and ∼12% respectively. We tested our first hypothesis that in older humans inhibition of NO would decrease hyperaemia, but that inhibition of PGs would increase hyperaemia by blocking vasoconstrictor PGs. Fifteen older subjects (65 ± 3 years) performed dynamic forearm exercise for 20 min (20 contractions min-1). Forearm blood flow (FBF) was measured beat-to-beat with Doppler ultrasound, while saline or drugs were infused sequentially via brachial artery catheter in the exercising forearm. After achieving steady-state exercise, l-NAME (25 mg) was infused over 5 min to inhibit NO synthase. After a further 2 min of exercise (saline), ketorolac (6 mg) was infused over 5 min to inhibit PGs, followed by a futher 3 min of exercise with saline. Drug order was reversed in seven subjects. l-NAME reduced steady-state exercise hyperaemia by 12 ± 3% in older subjects (P < 0.01), whereas ketorolac had no net effect on blood flow (3 ± 6%, P > 0.4). The effects of l-NAME and ketorolac were independent of drug order. By comparing these results with our previous results in young adults, we tested our second hypothesis that in older humans inhibition of NO or PGs would have less impact on exercise hyperaemia due to less vasodilatation from these signals. Our results suggest that, compared with young adults, in older humans the relative contribution of NO to exercise hyperaemia is reduced ∼45% (22 ± 4 versus 12 ± 3%), but the role of PG in mediating vasodilatation is lost in ageing human skeletal muscle. Lower exercise hyperaemia in older humans may be mediated in part by less NO- and PG-mediated vasodilatation during exercise.

AB - In older humans, infusions of endothelial agonists suggest endothelial dysfunction, due in part to less nitric oxide (NO)- and prostaglandin (PG)-mediated vasodilatation, and a shift toward PG-mediated vasoconstriction. Ageing can also be associated with lower exercise blood flow (exercise hyperaemia), but the vascular mechanisms mediating this remain unknown. Notably, in young adults, inhibition of NO and PGs during exercise decreases exercise hyperaemia by ∼20 and ∼12% respectively. We tested our first hypothesis that in older humans inhibition of NO would decrease hyperaemia, but that inhibition of PGs would increase hyperaemia by blocking vasoconstrictor PGs. Fifteen older subjects (65 ± 3 years) performed dynamic forearm exercise for 20 min (20 contractions min-1). Forearm blood flow (FBF) was measured beat-to-beat with Doppler ultrasound, while saline or drugs were infused sequentially via brachial artery catheter in the exercising forearm. After achieving steady-state exercise, l-NAME (25 mg) was infused over 5 min to inhibit NO synthase. After a further 2 min of exercise (saline), ketorolac (6 mg) was infused over 5 min to inhibit PGs, followed by a futher 3 min of exercise with saline. Drug order was reversed in seven subjects. l-NAME reduced steady-state exercise hyperaemia by 12 ± 3% in older subjects (P < 0.01), whereas ketorolac had no net effect on blood flow (3 ± 6%, P > 0.4). The effects of l-NAME and ketorolac were independent of drug order. By comparing these results with our previous results in young adults, we tested our second hypothesis that in older humans inhibition of NO or PGs would have less impact on exercise hyperaemia due to less vasodilatation from these signals. Our results suggest that, compared with young adults, in older humans the relative contribution of NO to exercise hyperaemia is reduced ∼45% (22 ± 4 versus 12 ± 3%), but the role of PG in mediating vasodilatation is lost in ageing human skeletal muscle. Lower exercise hyperaemia in older humans may be mediated in part by less NO- and PG-mediated vasodilatation during exercise.

UR - http://www.scopus.com/inward/record.url?scp=33846979103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846979103&partnerID=8YFLogxK

U2 - 10.1113/jphysiol.2006.124313

DO - 10.1113/jphysiol.2006.124313

M3 - Article

C2 - 17138603

AN - SCOPUS:33846979103

VL - 579

SP - 227

EP - 236

JO - Journal of Physiology

JF - Journal of Physiology

SN - 0022-3751

IS - 1

ER -